comparemela.com

Latest Breaking News On - Han li kang rituximab - Page 1 : comparemela.com

Fosun Pharma Announces 2022 Annual Results: Achieved Steady Growth with Revenue from Record High Innovative Products and Global Commercialization Capability Improvement

Performance Highlights: During the reporting period, the revenue was RMB 43.952 billion, with a year-on-year growth of 12.66%; the net profit after deducting extraordinary gain or loss attributable. | March 28, 2023

Fosun Pharma 2021 Annual Results Announcement: Accelerating the Globalization Comprehensively

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.